Research Groups

Frank Brombacher

Cancer Genomics

Group Leader

Research Interests and Description

Group Members

Luiz Zerbini

International Centre for Genetic Engineering and Biotechnology
Wernher and Beit Building (South)
Anzio Road, Observatory 7925
Cape Town, South Africa

E-mail: luiz.zerbiniicgeb.org
Tel.: +27-21-650-7627
Fax: +27-21-406-6060

Education

University of Sao Paulo (USP),Molecular Virology,  São Paulo, Brazil, PhD, 1999
Federal University of Sao Paulo, Paulista Medicine School,  São Paulo, Brazil, Master in Science, 1993
Campinas State University (UNICAMP),  Campinas, Brazil, BSc in Biomedical Sciences, 1989

Career History

Since 2009, Group Leader Cancer Genomics Group, International Centre for Genetic engineer and Biotechnology, Cape Town, South Africa
2004-2009, Faculty Instructor in Medicine, Harvard Medical School, Boston, USA
2004-2009, Associate Director, Research Proteomics, BIDMC Genomics Center and DFHC Proteomics Core, Boston, USA
2003-2004, Senior Research Scientist, BIDMC Genomics Center, Harvard Medical School, Boston, USA
1999-2003, Postdoctoral Fellow, BIDMC Genomics Center, Harvard Medical School, Boston, USA
1994-1995, Assistant Professor, Department of Microbiology, Paulista Medicine School, São Paulo, Brazil

Teaching Activity

2005-2009, Scientific Advisor, Continuing Umbrella of Research Experience (CURE), Dana-Farber/Harvard Cancer Center, Boston USA
2004-2006, Scientific Advisor, Project Success, Office of Diversity and Community Partnership at Harvard Medical School, Boston, USA
2002, Lecturer, CBAB Course, Brazilian-Argentinean Biotechnology Center/Partnership, São Paulo, Brazil
1996-1999, Lecturer, Biological Science Course, Campinas State University, São Paulo, Brazil
1994-1995, Assistant Professor, Department of Microbiology, Paulista Medicine School, São Paulo, Brazil
1992-1993, Lecturer, Biomedical Sciences Course, Paulista School of Medicine, São Paulo, Brazil

Scientific Activity

The overall goals of the laboratory are to utilize genomics and proteomics tools and signal transduction resources to accelerate comparative analysis of aberrant gene expression in carcinogenesis and to study alterations in signal transduction pathways during development of cancers. Areas of research include: regulation of gene expression by transcription factors, the role of receptor tyrosine kinases in cancer malignancies, aberrant gene expression in carcinogenesis and alterations in signal transduction pathways and gene translocations.

Selected publications

Zerbini LF on PubMed

Paccez J.D., Vogelsang M., Parker MIand Zerbini L.F. 2014. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. International Journal of Cancer.  134: 1024-33.

Zerbini L.F., Kumar M.K., Vasconcellos J.F., Paccez J.D., Gu X., Kung A.L., Libermann T.A. 2014. Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Molecular Cancer Therapeutics. 13:1929-41.

Mello P.A., Filippi-Chiela E.C., Nascimento J., Beckenkamp A., Santana D.B., Kipper F., Casali E.A., Bruno A., Paccez J.D., Zerbini L.F., Wink M.R., Lenz G., Buffon A. 2014 Adenosine Uptake is the Major Effector of Extracellular ATP Toxicity in Human Cervical Cancer Cells.Molecular Biology of the Cell. 25:2905-18

Paccez J.D., Vasques G.J., Bhasin M., Correa R.G., Vasconcellos J.F., Gu X., Libermann T.L. and Zerbini L.F. 2013. The tyrosine receptor kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth. Oncogene. 32:689-98s.

Li J., Weinberg M.S, Zerbini L.F and Prince S. 2013. The oncogenic TBX3 is a downstream target and mediator of the TGF-β1 signalling pathway. Molecular Biology of the Cell 24:3569-76.

Duncan K., Schäfer G., Vava A., Parker M.I and Zerbini L.F. 2012. Targeting neddylation in cancer therapy. Review. Future Oncology 8: 1461-70.

Tamura R.E, de Vasconcellos J.F, Sarkar D., Libermann T.A, Fisher P.B and Zerbini L.F. 2012.GADD45 proteins: central players in tumorigenesis. Review. Current Molecular Medicine 12(5):634-51.

Zerbini L.F, Tamura R.E, Correa R.G, Czibere A., Cordeiro J., Bhasin M., Simabuco F.M, Wang Y., Gu X., Li L, Sarkar D, Zhou J.R, Fisher P.B  and Libermann T.A. 2011. Combinatorial effect of Non-Steroidal Anti-inflammatory Drugs and NF-kB inhibitors in ovarian cancer therapy. Plos One 6:e24285.

Bruns I., Czibere A.,  Fischer J.C, Roels F., Cadeddu R.P, Buest S., Bruennert DHuenerlituerkoglu, NH Stoecklein A.N, Singh R, Zerbini L.F, Jager  M, Kobbe G, Gattermann N, Kronenwett R, Brors B and Haas R.2009.  The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia. 23:892-9.

Gu X., Zerbini L.F, Otu H, Joseph M.G, Grall F., Correa R.G, Libermann T.A 2007. Reduced PDEF expression leads to an increase in cell motility, invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Research 67: 4219-4226.

Zerbini LF, Czibere A, Wang Y, Correa R.G, Out H, Joseph M, Takayasu Y, Silver M, Gu X, Li L, Sarkar D, Zhou JR., Fisher P.B and Libermann T.A. 2006. A novel pathway involving MDA-7/IL-24 mediates NSAID induced apoptosis of cancer cells. Cancer Research 66: 11922-31.

Libermann T.A and Zerbini L.F. 2006. Targeting Transcription factors for Cancer Gene Therapy. Review. Current Gene Therapy 6: 17-33.

Zerbini L.F and Libermann T.A. 2005. GADD45 deregulation in cancer: frequently methylated tumor suppressors and potential therapeutic targets. Clinical Cancer Research 11: 6409-6413.

Zerbini L.F, Wang Y, Czibere A, Correa R.G, Cho J.Y, Ijiri K, Wei W, Joseph M, Gu X, Grall F, Goldring M.B, Zhou J.R and Libermann T.A. 2004.NF-kB mediated repression of GADD45a and g is essential for cancer cell survival. Proc Natl Acad Sci USA 101:13618-13623.

Zhou J.R, Yu L, Zerbini L.F, Libermann T.A and Blackburn GL. 2004. Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer 110:800-806.

Zerbini L.F, Wang Y, Cho JY and Libermann T.A. 2003. Constitutive activation of NF-kB p50/p65 and Fra-1 and JunD is essential for deregulated IL-6 expression in prostate cancer. Cancer Research 63:2206-2215.

 

ICGEB Cape Town

Wernher and Beit Building (South)
UCT Campus
Anzio Road
Observatory 7925
Cape Town
SOUTH AFRICA
Tel: +27-21-4066335
Fax: +27-21-4066060
capetownicgeb.org

 

tl_files/iTunes_Badge_Color_master_10251024.png

 


tl_files/FB.png
 tl_files/Twitter_logo_blue-1def.png tl_files/rss.png
tl_files/LinkedIn-InBug-2CRev2.png tl_files/YouTube.png